Scan test to find CD46-positive multiple myeloma lesions
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This Phase 1 study tests a new special scan marker (a radioactive imaging agent) to see whether it can detect certain multiple myeloma spots in the body. If it works, it may help doctors better locate disease using a PET-style scan.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be an adult (age 18 or older) with confirmed multiple myeloma
- Your PET/CT or PET/MRI scan must show at least one myeloma lesion that looks “hot” (brighter than the liver)
- You must have acceptable liver blood tests: bilirubin, AST, and ALT below set limits
- You must have acceptable kidney function (creatinine clearance at least 30 mL/min or creatinine not too high)
- You must be able to read and sign the informed consent form
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares two types of PET/CT scans to see which one better finds lesions (areas of disease) in people with newly diagnosed multiple myeloma. If you qualify, you may help doctors choose the most useful scan to guide care.
This early-stage trial tests a new radioactive tracer called [68Ga]Ga-R54 that helps doctors see certain advanced cancers (like breast, lung, colon, ovary, pancreas, or multiple myeloma) on PET scans. The tracer targets a specific protein (CXCR4) found on cancer cells, which may help doctors better detect and understand your cancer.
This trial tests a new type of PET scan that uses a radioactive tracer (68Ga-BCMA) to find active multiple myeloma cells in your body. It may help doctors better detect and monitor the disease.
This study uses a special PET scan to look for multiple myeloma in your body. It may help doctors see where the disease is and how active it is.
This trial tests whether a special PET/CT scan (using fluciclovine, a radioactive tracer) can more clearly see multiple myeloma in the body. It may help doctors evaluate the extent of the disease and guide treatment decisions.
This trial compares a new type of PET/MR scan (using a radioactive tracer called Ga-68 PentixaFor) with standard imaging to see if it can better detect multiple myeloma at diagnosis and during follow-up. It may help improve staging and treatment planning.
Hear when a new Multiple myeloma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.